# Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

> **NCT07435038** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Advanced Solid Tumors

## Interventions

- **DRUG:** BPI-572270

## Key facts

- **NCT ID:** NCT07435038
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-12
- **Primary completion:** 2028-12-28
- **Final completion:** 2029-10-28
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07435038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07435038, "Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT07435038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*